期刊
PLOS ONE
卷 7, 期 1, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0029863
关键词
-
资金
- U.S. National Cancer Institute [RO1 CA 079218-07]
- Portuguese Fundacao para a Ciencia e Tecnologia [PTDC/CVT/71084/2006]
- Fundação para a Ciência e a Tecnologia [PTDC/CVT/71084/2006] Funding Source: FCT
Recent findings regarding DII4 function in physiological and pathological conditions indicate that this Notch ligand may constitute an important therapeutic target. DII4 appears to be a major anti-angiogenic agent, occupying a central role in various angiogenic pathways. The first trials of anti-DII4 therapy in mice demonstrated a paradoxical effect, as it reduced tumor perfusion and growth despite leading to an increase in vascular density. This is seen as the result of insufficient maturation of the newly formed vasculature causing a circulatory defect and increased tumor hypoxia. As DII4 function is known to be closely dependent on expression levels, we envisioned that the therapeutic anti-DII4 dosage could be modulated to result in the increase of adequately functional blood vessels. This would be useful in conditions where vascular function is a limiting factor for recovery, like wound healing and tissue hypoxia, especially in diabetic patients. Our experimental results in mice confirmed this possibility, revealing that low dosage inhibition of DII4/Notch signaling causes improved vascular function and accelerated wound healing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据